The European Cancer Congress 2015

login
My congress planner

Searchable Programme for ECC2015

Keyword / Author:
  • 26
    SAT
    10:30 - 12:00
    Immunotherapy in Cancer

    Scientific Symposium: Cellular Immunotherapy of Cancer

    Chair: I. Melero (Spain)

    Co-Chair: C. Figdor (Netherlands)

    10:30
    Optimizing adoptive T-cell therapy
    Speaker: P. Hwu (USA)

    10:50
    Deploying gene-engineered T–cells in the cancer battlefield
    Speaker: C. June (USA)

    11:10
    Making the most of dendritic cell-based immunotherapy
    Speaker: C. Figdor (Netherlands)

    11:30
    Is cancer immunosurveillance relevant?
    Speaker: J. Galon (France)

    11:50
    Discussion & Roundup

  • 26
    SAT
    15:15 - 16:15
    Immunotherapy in Cancer

    Special Session: Combining Radiation and Immunotherapy

    Chair: A. Melcher (United Kingdom)

    15:15
    Molecular basis for radiotherapy in synergy with immunotherapy
    Speaker: S. Demaria (USA)

    15:25
    Radiotherapy, immunotherapy and virotherapy riddles
    Speaker: K. Harrington (United Kingdom)

    15:35
    Learning radioimmunotherapy
    Speaker: P. Beckhove (Germany)

    15:45
    Discussion

  • 27
    SUN
    09:15 - 10:25
    Poster board nr
    Abstract nr
    Immunotherapy in Cancer

    Proffered Paper Session: Immunotherapy in Cancer I

    Chair: I. Melero (Spain)

    09:15
    14LBA
    LATE BREAKING ABSTRACT:Atezolizumab monotherapy vs docetaxel in 2L/3L non-small cell lung cancer: Primary analyses for efficacy, safety and predictive biomarkers from a randomized phase II study (POPLAR)
    J. Vansteenkiste, L. Fehrenbacher, A.I. Spira, J. Mazieres, K. Park, D. Smith, A. Artal-Cortes, C. Lewanski, F. Braiteh, J. Yi, P. He, M. Kowanetz, D. Waterkamp, M. Ballinger, D.S. Chen, A. Sandler, A. Rittmeyer
    Display abstract

    09:25
    15LBA
    LATE BREAKING ABSTRACT: High tumoral IFNγ mRNA, PD-L1 protein, and combined IFNγ mRNA/PD-L1 protein expression associates with response to durvalumab (anti-PD-L1) monotherapy in NSCLC patients
    B.W. Higgs, P.B. Robbins, J.A. Blake-Haskins, W. Zhu, C. Morehouse, P.Z. Brohawn, M.C. Rebelatto, Y. Yao, X. Jin, L. Shi, K. Ranade
    Display abstract

    09:35
    16LBA
    LATE BREAKING ABSTRACT: Phase II, single-arm trial (BIRCH) of atezolizumab as first-line or subsequent therapy for locally advanced or metastatic PD-L1-selected non-small cell lung cancer (NSCLC)
    B. Besse, M. Johnson, P.A. Jänne, M. Garassino, W.E.E. Eberhardt, S. Peters, C.K. Toh, T. Kurata, Z. Li, M. Kowanetz, S. Mocci, A. Sandler, N.A. Rizvi
    Display abstract

    09:45
    Discussant : L. Paz-Ares (Spain)

    09:55
    17LBA
    LATE BREAKING ABSTRACT: Results from an open-label, randomized, controlled Phase 3 study investigating IMA901 multipeptide cancer vaccine in patients receiving sunitinib as first-line therapy for advanced/metastatic RCC
    B. Rini, A. Stenzl, R. Zdrojowy, M. Kogan, M. Shkolnik, S. Oudard, S. Weikert, S. Bracarda, S. Crabb, J. Bedke, J. Ludwig, D. Maurer, R. Mendrzyk, A. Mahr, J. Fritsche, T. Weinschenk, H. Singh, A. Kirner, C. Reinhardt, T. Eisen
    Display abstract

    10:05
    18LBA
    LATE BREAKING ABSTRACT: PD-L2 expression in human tumors: relevance to anti-PD-1 therapy in cancer
    J. Yearley, C. Gibson, N. Yu, C. Moon, E. Murphy, T. McClanahan
    Display abstract

    10:15
    Discussant : I. Melero (Spain)

  • 27
    SUN
    09:15 - 11:15
    Immunotherapy in Cancer

    Educational Symposium: Advances in Cancer Therapy Through Modulation of the Immune System

    Chair: B. Van den Eynde (Belgium)

    09:15
    Role of the immune system on the outcome of cancer therapy
    Speaker: A. Marabelle (France)

    09:40
    How does ionising radiation contribute to the induction of anti-tumour immunity?
    Speaker: G. Multhoff (Germany)

    10:05
    Targeting tumour microenvironment
    Speaker: P. Allavena (Italy)

    10:30
    Adoptive cell therapy
    Speaker: R. Hawkins (United Kingdom)

    10:55
    Discussion & Roundup

  • 27
    SUN
    17:05 - 18:55
    Poster board nr
    Abstract nr
    Immunotherapy in Cancer

    Proffered Paper Session: Immunotherapy in Cancer II

    Chair: I. Melero (Spain)

    Chair: I. Melero (Spain)

    Chair: A. Marabelle (France)

    Chair: A. Marabelle (France)

    17:05
    500
    Pembrolizumab (MK-3475) for PD-L1-positive squamous cell carcinoma (SCC) of the anal canal: Preliminary safety and efficacy results from KEYNOTE-028
    P.A. Ott, S.A. Piha-Paul, P. Munster, M.J. Pishvaian, E. Van Brummelen, R. Cohen, C. Gomez-Roca, S. Ejadi, M. Stein, E. Chan, M. Simonelli, A. Morosky, S.S. Yuan, M. Koshiji, J. Bennouna
    Display abstract

    17:20
    501
    Efficacy and safety of nivolumab in patients with metastatic renal cell carcinoma who were treated beyond progression in a randomized phase 2 dose-ranging trial
    S. George, R.J. Motzer, H. Hammers, B. Redman, T. Kuzel, S.S. Tykodi, E. Plimack, J. Jiang, I. Waxman, B.I. Rini
    Display abstract

    17:35
    502
    Pembrolizumab (MK-3475) for patients (pts) with advanced colorectal carcinoma (CRC): Preliminary results from KEYNOTE-028
    B.H. O'Neil, J. Wallmark, D. Lorente, E. Elez, J. Raimbourg, C. Gomez-Roca, S. Ejadi, S.A. Piha-Paul, R.A. Moss, L.L. Siu, K. Dotti, A. Santoro, M. Gould, S.S. Yuan, M. Koshiji, S.W. Han
    Display abstract

    17:50
    503
    Pneumonitis with anti-PD-1/PD-L1 therapy
    J. Naidoo, J. Cunningham, K.M. Woo, M.D. Hellmann, M.A. Postow, A.E. Drilon, J.E. Chaft, A.M. Lesokhin, N.H. Segal, M.K. Callahan, C.M. Rudin, T. Iyriboz, J.D. Wolchok
    Display abstract

    18:05
    Discussant : K. Harrington (United Kingdom)

    18:15
    504
    Intratumoral delivery of Interleukin-12 DNA via in vivo electroporation leads to regression of injected and non-injected tumors in Merkel cell carcinoma: Final Results of a phase 2 study
    S. Bhatia, J. Iyer, D. Ibrani, A. Blom, D. Byrd, U. Parvathaneni, T. Diep, M.H. Le, R.H. Pierce, R. Heller, A. Daud, P. Nghiem
    Display abstract

    18:30
    505
    Clinical evidence of intra-tumoral immune activation and tumor targeting with RG7813, a CEA-targeted engineered IL-2 immunocytokine
    J. Tabernero, K. Homicsko, J.H. Schellens, O. Hoekstra, L. Van der Veen, I. Melero, G. Argilés, M. Mau-Sorensen, E. Angevin, H. Joensuu, E. Van Brummelen, C.W. Menke-van der Houven van Oordt, T. Nayak, S. Romagnoli, B. Reis, S. Soehrman Brossard, S. Evers, J. Saro, H. Verheul, U. Lassen
    Display abstract

    18:45
    Discussant : S. Demaria (USA)

Print / Download as PDF

Alerts